4-nitrophenyl-beta-D-galactoside

Identification

Generic Name
4-nitrophenyl-beta-D-galactoside
DrugBank Accession Number
DB02632
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 301.2494
Monoisotopic: 301.079766461
Chemical Formula
C12H15NO8
Synonyms
  • 1-O-(4-nitrophenyl)-β-D-galactopyranose
  • 1-O-(4-nitrophenyl)-β-D-galactose
  • 1-O-(p-nitrophenyl)-β-D-galactopyranose
  • 1-O-(p-nitrophenyl)-β-D-galactose
  • 1-O-[p-nitrophenyl]-beta-D-galactopyranose
  • 4-Nitrophenyl-beta-D-galactopyranoside
  • 4-nitrophenyl-β-D-galactopyranoside
  • 4-nitrophenyl-β-D-galactoside
  • 4-Nitrophenylgalactoside
  • p-Nitrophenyl beta-D-galactopyranoside
  • p-Nitrophenyl-beta-D-galactoside

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGalactoside O-acetyltransferaseNot AvailableEscherichia coli (strain K12)
UBeta-galactosidaseNot AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Phenolic glycosides
Alternative Parents
Hexoses / O-glycosyl compounds / Nitrobenzenes / Nitroaromatic compounds / Phenol ethers / Phenoxy compounds / Oxanes / Secondary alcohols / Oxacyclic compounds / Organic oxoazanium compounds
show 9 more
Substituents
Acetal / Alcohol / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Benzenoid / C-nitro compound / Hexose monosaccharide / Hydrocarbon derivative / Monocyclic benzene moiety / Monosaccharide
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monosaccharide derivative, beta-D-galactoside (CHEBI:355715)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
3150-24-1
InChI Key
IFBHRQDFSNCLOZ-YBXAARCKSA-N
InChI
InChI=1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-3-1-6(2-4-7)13(18)19/h1-4,8-12,14-17H,5H2/t8-,9+,10+,11-,12-/m1/s1
IUPAC Name
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
SMILES
OC[C@H]1O[C@@H](OC2=CC=C(C=C2)[N+]([O-])=O)[C@H](O)[C@@H](O)[C@H]1O

References

General References
Not Available
KEGG Compound
C04452
PubChem Compound
65115
PubChem Substance
46505977
ChemSpider
58625
ChEBI
355715
ChEMBL
CHEMBL157265
ZINC
ZINC000003956718
PDBe Ligand
147
PDB Entries
1jyw / 1krv / 2wgz / 3zyf / 4ccc / 4r6r

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.4 mg/mLALOGPS
logP-0.63ALOGPS
logP-0.66Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.2Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area142.52 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity66.5 m3·mol-1Chemaxon
Polarizability27.6 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8899
Blood Brain Barrier-0.5228
Caco-2 permeable-0.6121
P-glycoprotein substrateNon-substrate0.6525
P-glycoprotein inhibitor INon-inhibitor0.5651
P-glycoprotein inhibitor IINon-inhibitor0.8965
Renal organic cation transporterNon-inhibitor0.8543
CYP450 2C9 substrateNon-substrate0.7644
CYP450 2D6 substrateNon-substrate0.8428
CYP450 3A4 substrateSubstrate0.5517
CYP450 1A2 substrateNon-inhibitor0.5613
CYP450 2C9 inhibitorNon-inhibitor0.7906
CYP450 2D6 inhibitorNon-inhibitor0.8907
CYP450 2C19 inhibitorNon-inhibitor0.8161
CYP450 3A4 inhibitorNon-inhibitor0.9651
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.806
Ames testNon AMES toxic0.5538
CarcinogenicityNon-carcinogens0.8548
BiodegradationNot ready biodegradable0.7039
Rat acute toxicity2.4049 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7714
hERG inhibition (predictor II)Non-inhibitor0.7442
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-05ar-9560000000-cbd4260c86e0c49839ce
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-172.3642484
predicted
DarkChem Lite v0.1.0
[M-H]-161.66843
predicted
DeepCCS 1.0 (2019)
[M+H]+172.9967484
predicted
DarkChem Lite v0.1.0
[M+H]+163.84138
predicted
DeepCCS 1.0 (2019)
[M+Na]+171.7688484
predicted
DarkChem Lite v0.1.0
[M+Na]+170.52956
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Galactoside o-acetyltransferase activity
Specific Function
May assist cellular detoxification by acetylating non-metabolizable pyranosides, thereby preventing their reentry into the cell.
Gene Name
lacA
Uniprot ID
P07464
Uniprot Name
Galactoside O-acetyltransferase
Molecular Weight
22798.89 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Magnesium ion binding
Specific Function
Not Available
Gene Name
lacZ
Uniprot ID
P00722
Uniprot Name
Beta-galactosidase
Molecular Weight
116482.045 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at August 01, 2020 13:44